KR20150010953A - 경구 투여를 위한 폴리펩티드 로딩된 poca 나노입자 - Google Patents

경구 투여를 위한 폴리펩티드 로딩된 poca 나노입자 Download PDF

Info

Publication number
KR20150010953A
KR20150010953A KR20147031771A KR20147031771A KR20150010953A KR 20150010953 A KR20150010953 A KR 20150010953A KR 20147031771 A KR20147031771 A KR 20147031771A KR 20147031771 A KR20147031771 A KR 20147031771A KR 20150010953 A KR20150010953 A KR 20150010953A
Authority
KR
South Korea
Prior art keywords
nanoparticles
nanoparticle
peptide
exendin
metabolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20147031771A
Other languages
English (en)
Korean (ko)
Inventor
션 매튜 클레버랜드
마크 앤드류 파울리크
스테판 살로몬
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20150010953A publication Critical patent/KR20150010953A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR20147031771A 2012-05-16 2013-05-16 경구 투여를 위한 폴리펩티드 로딩된 poca 나노입자 Withdrawn KR20150010953A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647633P 2012-05-16 2012-05-16
US61/647,633 2012-05-16
PCT/IB2013/000964 WO2013171570A1 (en) 2012-05-16 2013-05-16 Polypeptide loaded poca nanoparticles for oral administration

Publications (1)

Publication Number Publication Date
KR20150010953A true KR20150010953A (ko) 2015-01-29

Family

ID=48577784

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147031771A Withdrawn KR20150010953A (ko) 2012-05-16 2013-05-16 경구 투여를 위한 폴리펩티드 로딩된 poca 나노입자

Country Status (10)

Country Link
US (1) US20150342897A1 (enExample)
EP (1) EP2849775A1 (enExample)
JP (1) JP2015523332A (enExample)
KR (1) KR20150010953A (enExample)
CN (1) CN104411321A (enExample)
AU (1) AU2013261214A1 (enExample)
CA (1) CA2873536A1 (enExample)
IN (1) IN2014DN09297A (enExample)
RU (1) RU2014150850A (enExample)
WO (1) WO2013171570A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104799440B (zh) * 2014-01-23 2016-06-08 香港纺织及成衣研发中心有限公司 改善代谢综合症的功能服及其制造方法
CN105342999A (zh) * 2014-08-18 2016-02-24 山东绿叶制药有限公司 艾塞那肽口服纳米粒
CN109675020B (zh) * 2019-01-11 2021-05-04 浙江大学 一种口服glp-1多肽类纳米制剂及其制备方法和应用
WO2022132454A1 (en) 2020-12-18 2022-06-23 Spectrum Brands, Inc. Grooming tool for animal and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0512042B1 (en) 1990-01-24 1998-04-08 BUCKLEY, Douglas I. Glp-1 analogs useful for diabetes treatment
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
WO1998005351A1 (en) 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
CA2299425A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
CA2309356C (en) 1997-11-14 2010-09-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
EP1066314B1 (en) 1997-11-14 2007-12-26 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
CA2320371C (en) 1998-02-13 2012-01-17 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1355942B1 (en) 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
JP4949838B2 (ja) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
JP5570721B2 (ja) 2005-06-17 2014-08-13 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ナノ粒子の製造方法、システム、及び材料
US20080138418A1 (en) * 2006-12-07 2008-06-12 Tong Shen Enterprise Co., Ltd. Nanoparticles composed of alkyl-cyanoacrylate polymers
US7976759B2 (en) 2007-10-12 2011-07-12 Liquidia Technologies, Inc. System and method for producing particles and patterned films

Also Published As

Publication number Publication date
RU2014150850A (ru) 2016-07-10
JP2015523332A (ja) 2015-08-13
AU2013261214A1 (en) 2014-11-20
CN104411321A (zh) 2015-03-11
IN2014DN09297A (enExample) 2015-07-10
CA2873536A1 (en) 2013-11-21
US20150342897A1 (en) 2015-12-03
WO2013171570A1 (en) 2013-11-21
EP2849775A1 (en) 2015-03-25

Similar Documents

Publication Publication Date Title
JP7354350B2 (ja) グルカゴン受容体選択的ポリペプチド及びその使用方法
Chalasani et al. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles
Hinds et al. PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis
Araujo et al. In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy
Wong et al. The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation
CN101854914B (zh) 胰岛淀粉样多肽及其类似物的稳定制剂
Chen et al. Long-acting release formulation of exendin-4 based on biomimetic mineralization for type 2 diabetes therapy
Seo et al. Sustained release of exendin 4 using injectable and ionic-nano-complex forming polymer hydrogel system for long-term treatment of type 2 diabetes mellitus
Soudry-Kochavi et al. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach
JP2021167357A (ja) 錠剤コアと即時放出コーティングとを含む経口ｇｌｐ−１投与用の医薬組成物
Alavi et al. Developing GLP-1 conjugated self-assembling nanofibers using copper-catalyzed alkyne–azide cycloaddition and evaluation of their biological activity
Jakhar et al. Fat fighting liraglutide based nano-formulation to reverse obesity: design, development and animal trials
Baig et al. Design, synthesis and evaluation of DNA nano-cubes as a core material protected by the alginate coating for oral administration of anti-diabetic drug
Lear et al. Engineering of a potent, long-acting NPY2R agonist for combination with a GLP-1R agonist as a multi-hormonal treatment for obesity
Zhang et al. In vitro and in vivo sustained release of exenatide from vesicular phospholipid gels for type II diabetes
KR20150010953A (ko) 경구 투여를 위한 폴리펩티드 로딩된 poca 나노입자
Hasan et al. Oral GLP1 gene delivery by an antibody-guided nanomaterial to treat type 2 diabetes mellitus
Han et al. Micellar nanomedicine of novel fatty acid modified Xenopus glucagon-like peptide-1: improved physicochemical characteristics and therapeutic utilities for type 2 diabetes
Reboredo et al. Oral administration of zein-based nanoparticles reduces glycemia and improves glucose tolerance in rats
Petersen et al. Designing poly-agonists for treatment of metabolic diseases: challenges and opportunities
Lee Glucagon‐Like Peptide‐1 Formulation–the Present and Future Development in Diabetes Treatment
Kwak et al. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats
Prajapati et al. Current status of therapeutic peptides for the management of diabetes mellitus
Son et al. Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects
M Ramesan et al. Recent advances in the oral delivery of insulin

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141112

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid